PALO ALTO, Calif., April 19, 2018 /PRNewswire/ -- Varian (NYSE:
VAR) today announced it is incorporating new imaging technologies
in the Halcyon™ 2.0 treatment system to expand its
capabilities and ability to deliver high quality cancer care
globally. First announced in May
2017, Halcyon is revolutionizing the clinical workflow and
simplifying and enhancing virtually every aspect of image-guided
intensity modulated radiotherapy (IMRT). Halcyon 2.0 will feature
kV Cone-beam CT (CBCT) and Iterative CBCT imaging for better soft
tissue definition.
Solidifying Halcyon's reputation of delivering advanced
treatments while enhancing patient comfort and increasing ease of
use for healthcare providers, Halcyon 2.0 is capable of kV CBCT
images in approximately 15 seconds. This enhanced imaging
capability helps ensure proper patient positioning while also
accelerating the treatment workflow.
"We have been very happy with the strong positive response
Halcyon has received from the global cancer care community," said
Kolleen Kennedy, president of
Varian's Oncology Systems business. "By working closely with our
clinical partners, we have been able to quickly evolve the Halcyon
system with these new imaging technologies, provide a pathway to
adaptive radiotherapy and continue our efforts of advancing
high-quality and cost-effective cancer care worldwide."
Halcyon provides highly targeted radiotherapy on a platform
that's intuitive for clinicians and comfortable for patients. The
streamlined workflow requires only nine steps from the start to the
end of treatment compared to up to more than 30 steps with older
technologies. Halcyon is well suited to handle the majority of
cancer patients, offering advanced treatments for prostate, breast,
head & neck, and many other forms of cancer.
Halcyon 2.0 is currently Works in Progress and not available for
sale. For more information on Halcyon, visit
www.varian.com/halcyon.
About Varian
Varian is a leader in developing and
delivering cancer care solutions, and is focused on creating a
world without fear of cancer. Headquartered in Palo Alto, California, Varian employs
approximately 6,500 people around the world. For more
information, visit http://www.varian.com and follow @VarianMedSys
on Twitter.
Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-expands-capabilities-of-halcyon-treatment-system-with-new-imaging-technologies-300632630.html
SOURCE Varian